Prostate Cancer and Racial Equity: Analysis of Barriers to Health Care Access

Authors

DOI:

https://doi.org/10.32635/2176-9745.RBC.2026v72n1.5391

Keywords:

Prostatic Neoplasms/epidemiology, Race Factors/ethics, Health Services Accessibility

Abstract

Introduction: In Brazil, prostate cancer is the second most common type of cancer among men, being more prevalent in older adults. However, Black men have higher incidence and mortality rates, as well as later diagnoses and reduced access to appropriate therapies, reflecting structural racial, socioeconomic, and geographic inequalities. Objective: To analyze the barriers to health care access for Black men with prostate cancer, exploring the diagnostic process, treatment choices, and adherence to therapy. Method: Integrative literature review based on searches at the databases PubMed, EMBASE, Web of Science, Scopus, and BVS. The descriptors “Prostatic Neoplasms,” “Health Services Accessibility,” and “Race Factors” were used, combined with Boolean operators, resulting in 32 studies included in the review. Results: The studies were organized into six categories: (1) Epidemiology and racial disparities, (2) Specific risk factors, (3) Access and barriers to early diagnosis, (4) Treatment and clinical outcomes, (5) Psychosocial aspects and quality of life, and (6) Public policies and strategies to reduce inequalities. The analyses revealed systemic inequalities in access to diagnosis, treatment, and psychosocial support, as well as the influence of structural racism and underrepresentation in researches. Conclusion: Health care access for Black men with prostate cancer is limited by complex and interdependent barriers, requiring intersectoral strategies, inclusive public policies, culturally sensitive training, and expansion of oncological equity.

Downloads

Download data is not yet available.

References

Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730. doi: https://doi.org/10.3390/molecules27175730 DOI: https://doi.org/10.3390/molecules27175730

Markl AM, Nieder D, Sandoval-Bojorquez DI, et al. Heterogeneity of tumor biophysical properties and their potential role as prognostic markers. arXiv. 2024. doi: https://doi.org/10.48550/arXiv.2411.19532 DOI: https://doi.org/10.47248/chp2401020011

Instituto Nacional de Câncer [Internet]. Rio de Janeiro: INCA; 2000. Câncer de próstata, 2022 jun 4 [acesso 2025 maio 29]. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/prostata

World Health Organization. Guide to cancer early diagnosis [Internet]. WHO: Geneva; 2017 [acesso 2025 jun 25]. Disponível em: https://www.who.int/publications/i/item/guide-to-cancer-early-diagnosis

Lillard Junior JW, Moses KA, Mahal BA, et al. Racial disparities in black men with prostate cancer: a literature review. Cancer. 2022;128(21):3787-95. doi: https://doi.org/10.1002/cncr.34433 DOI: https://doi.org/10.1002/cncr.34433

Souza ASVR, Melo RL, Araújo BRO. Raça, gênero e classe uma revisão integrativa sobre os impactos dos determinantes sociais da saúde na infecção por covid-19. CBS [Internet]. 2022[acesso 2025 jun 26];7(2):99. Disponível em: https://periodicosgrupotiradentes.emnuvens.com.br/cdgsaude/article/view/9934

Anunciação D, Pereira LL, Silva HP, et al. (Des)caminhos na garantia da saúde da população negra e no enfrentamento ao racismo no Brasil. Ciênc saúde coletiva. 2022;27(10):3861-70. doi: https://doi.org/10.1590/1413-812320222710.08212022 DOI: https://doi.org/10.1590/1413-812320222710.08212022en

Botelho LLR, Cunha CCA, Macedo M. O método da revisão integrativa nos estudos organizacionais. GeS. 2011;5(11):121-36. doi: https://doi.org/10.21171/ges.v5i11.1220 DOI: https://doi.org/10.21171/ges.v5i11.1220

Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enferm. 2008;17(4):758-64. doi: https://doi.org/10.1590/S0104-07072008000400018 DOI: https://doi.org/10.1590/S0104-07072008000400018

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: https://doi.org/10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71

Jayadevappa R, Malkowicz SB, Chhatre S, et al. Racial and ethnic variation in health resource use and cost for prostate cancer. BJU Int. 2010;106(6):801-8. doi: https://doi.org/10.1111/j.1464-410X.2010.09227.x DOI: https://doi.org/10.1111/j.1464-410X.2010.09227.x

Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589-604. doi: https://doi.org/10.1093/annonc/mdv257 DOI: https://doi.org/10.1093/annonc/mdv360

Pandit AA, Gressler LE, Halpern MT, et al. Differences in racial/ethnic disparities in patient care experiences between prostate cancer survivors and males without cancer: a SEER-CAHPS study. J Geriatr Oncol. 2023;14(6):101554. doi: https://doi.org/10.1016/j.jgo.2023.101554 DOI: https://doi.org/10.1016/j.jgo.2023.101554

Nyame YA, Gulati R, Heijnsdijk EAM, et al. The impact of intensifying prostate cancer screening in Black men: a model-based analysis. J Natl Cancer Inst. 2021;113(10):1336-42. doi: https://doi.org/10.1093/jnci/djab072 DOI: https://doi.org/10.1093/jnci/djab072

Vince RA Jr, Jamieson S, Mahal B, et al. examining the racial disparities in prostate cancer. Urology. 2022;163:107-11. doi: https://doi.org/10.1016/j.urology.2021.08.004 DOI: https://doi.org/10.1016/j.urology.2021.08.004

Azimi MS, Zaydman AM. Access to preventive health services among Black patients: transportation and systemic distribution barriers. J Natl Med Assoc [Internet]. 2023[acesso2025 jun 26];115(1):23-30. Disponível em: https://pubmed.ncbi.nlm.nih.gov/15483526/

Nocera L, Wenzel M, Collà Ruvolo C, et al. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. Urol Oncol. 2021;39(11):785.e11-785.e17. doi: https://doi.org/10.1016/j.urolonc.2021.04.004 DOI: https://doi.org/10.1016/j.urolonc.2021.04.004

Bagley A, Anscher MS, Choi S, et al. Factors affecting receipt of non-definitive therapy for high-risk prostate cancer: a National Cancer Database analysis. Int J Radiat Oncol Biol Phys. 2019;105(1):E452. doi: https://doi.org/10.1016/j.ijrobp.2019.06.1498 DOI: https://doi.org/10.1016/j.ijrobp.2019.06.1498

Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2004;96(18):1358-67. doi: https://doi.org/10.1093/jnci/djh259 DOI: https://doi.org/10.1093/jnci/djh259

Talcott JA, Spain P, Clark JA, et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer. 2007;109(8):1599-606. DOI: https://doi.org/10.1002/cncr.22583

Chen X, Cao Y, Katz AJ, et al. Effect of income on patient decision-making in localized prostate cancer. J Clin Oncol. 2021;39(sup 15):6552. DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.6552

Varghese SL, Grossfeld GD. The prostatic gland: malignancies other than adenocarcinomas. Radiol Clinics North Am. 2000;38(1):179-202. DOI: https://doi.org/10.1016/S0033-8389(05)70155-X

Church SJ, Pulianmackal AJ, Dixon JA, et al. Oncogenic signaling in the Drosophila prostate-like accessory gland activates a pro-tumorigenic program in the absence of proliferation. Dis Model Mech. 2025;18(4):dmm052001. doi: https://doi.org/10.1242/dmm.052001 DOI: https://doi.org/10.1242/dmm.052001

Miller DB, Markt SC, Nguyen CT, et al. Prostate cancer screening and young Black men: can early communication avoid later health disparities? J Cancer Educ. 2022;37(5):1460-5. doi: https://doi.org/10.1007/s13187-021-01984-6 DOI: https://doi.org/10.1007/s13187-021-01984-6

Trinh QD, Li H, Meyer CP, et al. Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016;27(8):989-98. doi: https://doi.org/10.1007/s10552-016-0776-8 DOI: https://doi.org/10.1007/s10552-016-0776-8

Wheeler SB, Reeder-Hayes KE, Carey LA. Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist. 2013;18(9):986-93. doi: https://doi.org/10.1634/theoncologist.2013-0243 DOI: https://doi.org/10.1634/theoncologist.2013-0243

Press DJ, Shariff-Marco S, Lichtensztajn DY, et al. Contributions of social factors to disparities in prostate cancer risk profiles among Black men and non-Hispanic White men with prostate cancer in California. Cancer Epidemiol Biomarkers Prev. 2022;31(2):404-12. doi: https://doi.org/10.1158/1055-9965.epi-21-0697 DOI: https://doi.org/10.1158/1055-9965.EPI-21-0697

Wong MS, Grande DT, Mitra N, et al. Racial differences in geographic access to medical care as measured by patient report and geographic information systems. Med Care. 2017;55(9):817-22. doi: https://doi.org/10.1097/MLR.0000000000000774 DOI: https://doi.org/10.1097/MLR.0000000000000774

Labban M, Stone BV, Steele GL, et al. A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for black men with prostate cancer in Massachusetts. Cancer. 2024;130(Sup20):3590-601. doi: https://doi.org/10.1002/cncr.35366 DOI: https://doi.org/10.1002/cncr.35366

Minarim DS, Riviere P, Deshler LN, et al. The impact of perceived healthcare discrimination on health outcomes among patients with prostate cancer across racial and ethnic groups. J Clin Oncol. 2024;42(4 Supl):268. doi: https://doi.org/10.1200/JCO.2024.42.4_suppl.268 DOI: https://doi.org/10.1200/JCO.2024.42.4_suppl.268

Aladuwaka S, Alagan R, Singh R, et al. Health burdens and SES in Alabama: using geographic information system to examine prostate cancer health disparity. Cancers (Basel). 2022;14(19):4824. doi: https://doi.org/10.3390/cancers14194824 DOI: https://doi.org/10.3390/cancers14194824

Dee EC, Arega MA, Yang DD, et al. Disparities in refusal of locoregional treatment for prostate adenocarcinoma. JCO Oncol Pract. 2021;17(7):e1017-28. doi: https://doi.org/10.1200/OP.20.00839 DOI: https://doi.org/10.1200/OP.20.00839

Ishino FA, Rowan C, Das R, et al. Identifying risk profiles of malignant prostate cancer surgical delay using a person-centered approach to understand prostate cancer disparities: the constellation of health determinants using latent class analysis on cancer registry data. Am J Mens Health. 2020;14(6):1557988320984282. doi: https://doi.org/10.1177/1557988320984282 DOI: https://doi.org/10.1177/1557988320984282

Kan CK, Qureshi MM, Gupta A, et al Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety-net hospital. Adv Radiat Oncol. 2017;3(2):181-9. doi: https://doi.org/10.1016/j.adro.2017.12.002 DOI: https://doi.org/10.1016/j.adro.2017.12.002

Kinlock BL, Parker LJ, Bowie JV, et al. High levels of medical mistrust are associated with low quality of life among Black and White men with prostate cancer. Cancer Control. 2017;24(1):72-7. doi: https://doi.org/10.1177/107327481702400112

Bustillo NE, McGinty HL, Dahn JR, et al. Fatalism, medical mistrust, and pretreatment health-related quality of life in ethnically diverse prostate cancer patients. Psychooncology. 2017;26(3):323-9. doi: https://doi.org/10.1002/pon.4030 DOI: https://doi.org/10.1002/pon.4030

Rivas C, Matheson L, Nayoan J, et al. Ethnicity and the prostate cancer experience: a qualitative metasynthesis. Psychooncology. 2016;25(10):1147-56. doi: https://doi.org/10.1002/pon.4222 DOI: https://doi.org/10.1002/pon.4222

Hsieh CC, Thanos A, Mitropoulos D, et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer. 1999;80:699-703. DOI: https://doi.org/10.1002/(SICI)1097-0215(19990301)80:5<699::AID-IJC12>3.3.CO;2-Z

Hinyard LJ, Schwartz T, Keller J. Differences in psychosocial stressors between Black and White cancer patients. J Community Support Oncol. 2017;15(6):e314-20. doi: https://doi.org/10.12788/jcso.0366 DOI: https://doi.org/10.12788/jcso.0366

Merluzzi TV, Philip EJ, Zhang Z et al. Perceived discrimination, coping, and quality of life for African-American and Caucasian persons with cancer. Cultur Divers Ethnic Minor Psychol. 2015 Jul;21(3):337-44. doi: https://doi.org/10.1037/a0037543 DOI: https://doi.org/10.1037/a0037543

Gordon B-BE, Basak R, Carpenter WR, et al. Factors influencing prostate cancer treatment decisions for African American and white men. Cancer. 2019;125(10):1693-700. doi: https://doi.org/10.1002/cncr.31932 DOI: https://doi.org/10.1002/cncr.31932

Bersani H. Aportes teóricos e reflexões sobre o racismo estrutural no Brasil. Rev Extraprensa. 2018;11(2):175-96. doi: https://doi.org/10.11606/extraprensa2018.148025 DOI: https://doi.org/10.11606/extraprensa2018.148025

Do YK, Carpenter WR, Spain P, et al. Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control. 2010;21(1):31-40. doi: https://doi.org/10.1007/s10552-009-9431-y DOI: https://doi.org/10.1007/s10552-009-9431-y

Kinlock BL, Parker LJ, Bowie JV, et al. High levels of medical mistrust are associated with low quality of life among Black and White men with prostate cancer. Cancer Control. 2017;24(1):72-7. doi: https://doi.org/10.1177/107327481702400112 DOI: https://doi.org/10.1177/107327481702400112

Daum LM, Reamer EN, Ruterbusch JJ, et al. Patient knowledge and qualities of treatment decisions for localized prostate cancer. J Am Board Fam Med. 2017;30(3):288-97. doi: https://doi.org/10.3122/jabfm.2017.03.160298 DOI: https://doi.org/10.3122/jabfm.2017.03.160298

Published

2025-11-18

How to Cite

1.
Souza ADL de, Amorim LL, Leite LPG, Silva YYV, Silva AB da, Medeiros EMB de, Nascimento EGC do. Prostate Cancer and Racial Equity: Analysis of Barriers to Health Care Access. Rev. Bras. Cancerol. [Internet]. 2025 Nov. 18 [cited 2025 Dec. 4];72(1):e-095391. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/5391

Issue

Section

LITERATURE REVIEW